A 77-year-old man was diagnosed with lung adenocarcinoma and presented with bone and
liver metastases (cT1bN2M1c; stage IVB). The driver mutations were negative, and the
programmed cell death ligand 1 tumor proportion score was 80%. He underwent immune-checkpoint
inhibitor (ICI) therapy (pembrolizumab 200 mg/m2) every three weeks. Pembrolizumab immunotherapy was administered for a total of 35
cycles, all lung lesions disappeared (Fig. 1A), and the therapeutic outcome was considered a complete response.
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to The American Journal of the Medical SciencesAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Pneumonitis in patients treated with anti-programmed death-1/programmed death ligand 1 therapy.J Clin Oncol. 2017; 35: 709-717
- Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients.Eur Respir J. 2017; 501700050
Article info
Publication history
Published online: September 22, 2022
Accepted:
September 19,
2022
Received:
January 20,
2022
Identification
Copyright
© 2022 Southern Society for Clinical Investigation. Published by Elsevier Inc. All rights reserved.
